State Street SPDR S&P Pharmaceuticals ETF (XPH)
$64.15+3.07%Close
Snapshot
- 1 week
- +3.3%+4.5% vs SPY
- 1 month
- -4.1%-5.1% vs SPY
- Assets
- $258.7M
- Expense ratio
- 0.35%
- Fund type
- EQUITY
- Distribution yield
- 0.43%
- Dividend growth
- -45.8%
Signal: Call, Regime, Alignment, Score, ATR trend, HiLo flip, Coil, Exhaustion, Topping · Technicals (EMA stack, slope, squeeze, stochastic, MACD-Z, DI+) · Price & returns: 3 months, Year to date, 1 year · Fund: Income score, Valuation
Price & returns: 3 years, 5 years
Signal: Composite · Performance (Q-Score, Sharpe, Sortino, Calmar, CAGR, drawdown, alpha)
Signal evidence
Best Combo (today's action, held-out profit factor and family votes) · White Arrow (the call, its profit factor and closed trades) · Regime (today's regime and the regime model's profit factor) · Exhaustion (whether buyers or sellers are stretched today and the latest release)
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Fund
About
State Street SPDR S&P Pharmaceuticals ETF (XPH). SPDR Series Trust - SPDR S&P Pharmaceuticals ETF is an exchange traded fund launched by State Street Global Advisors, Inc. It is managed by SSGA Funds Management, Inc. It invests in public equity markets of the United States. The fund invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. It seeks to track the pe…
SEC filingsCIK 1064642
